Search for a trial

Erector Spinae Plane Block versus Thoracic Epidural Block in Elective Video-Assisted Thoracic Surgery (VATS): A Prospective Randomized Open Label non-inferiority Trial

Evaluate the non-inferiority of the ESP-block compared to the TEA in VATS lobectomy or wedge resection.

Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients, a proof-of-concept study.

Primary objectives:• to assess the safety of combining nivolumab, ipilimumab and up to 3 fractions of medium dose hypofractionated radiotherapy (mRT) to multiple tumor sites (1 to 4, with at least 1 site receiving 24Gy)• to explore the efficacy of…

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

The overall objective of this trial is to evaluate the efficacy and safety of pamrevlumab as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)

This study has been transitioned to CTIS with ID 2023-508443-40-00 check the CTIS register for the current data. Dual Primary Objectives:• To compare progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR) using…

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study has been transitioned to CTIS with ID 2023-506576-27-00 check the CTIS register for the current data. The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent…

Prediciting Radiation-Induced lung injury through patient-specific lung epithelial ORganoids

To demonstrate the validity of using patient-derived lung epithelial organoids, as a model of normal lung tissue, we aim to assess lung epithelial cell responses to ionizing radiation exposure and relate these to clinical outcome. In addition,…

Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum-based Chemotherapy (TROPION-Lung05)

This study has been transitioned to CTIS with ID 2024-511449-21-00 check the CTIS register for the current data. Primary:To assess the efficacy of DS-1062a, as measured by the ORR, as a treatment for subjects with NSCLC with actionable genomic…

AN OPEN-LABEL, EXPLORATORY STUDY ASSESSING THE FEASIBILITY OF SGM-101, A FLUOROCHROME-LABELED ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY FOR THE INTRAOPERATIVE DETECTION OF LUNG METASTASIS IN COLORECTAL CANCER

1. To determine the feasibility of SGM-101 for intraoperative imaging of colorectal lung metastases - Concordance between fluorescent signal and tumor status of resected tissue2. To define the optimal dose of SGM-101 for intraoperative imaging of…

A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER.

This study has been transitioned to CTIS with ID 2022-502482-17-00 check the CTIS register for the current data. This study will evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in patients…

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Advanced Tumors (study 209012)

Primary:To assess the safety, tolerability and determine recommended phase 2 dose (RP2D) of NY-ESO-1 and LAGE-1a specific T cells, alone or in combination with other agents, in HLA-A*02-positive participants with NY-ESO-1 and/or LAGE-1a positive…

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION.

This study has been transitioned to CTIS with ID 2022-502480-38-00 check the CTIS register for the current data. This study will evaluate the efficacy and safety of consolidation maintenance treatment consisting of atezolizumab and tiragolumab…

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER.

The objective for this study is to evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in patients with untreated extensive-stage small cell lung cancer (ES-SCLC)…

An exploratory study of durvalumab (MEDI4736) uptake during concurrent chemoradiotherapy in stage III NSCLC patients using 89Zr-labeled durvalumab PET

Primary Objectives:* To study early (1 week after start of cCRT) and late changes (after finishing cCRT) in durvalumab (MEDI4736) uptake in tumor and metastatic lymph nodes during cCRT * To study early and late changes in durvalumab (MEDI4736)…